PortalPublikationenClinical and functional outcome of assertive outreach for pa...

Clinical and functional outcome of assertive outreach for patients with schizophrenic disorder: Results of a quasi-experimental controlled trial

Standard

Clinical and functional outcome of assertive outreach for patients with schizophrenic disorder: Results of a quasi-experimental controlled trial. / Kästner, D; Büchtemann, D; Warnke, I; Radisch, J; Baumgardt, J; Giersberg, S; Kopke, K; Moock, J; Kawohl, W; Rössler, W.

in: EUR PSYCHIAT, Jahrgang 30, Nr. 6, 09.2015, S. 736-42.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kästner, D, Büchtemann, D, Warnke, I, Radisch, J, Baumgardt, J, Giersberg, S, Kopke, K, Moock, J, Kawohl, W & Rössler, W 2015, 'Clinical and functional outcome of assertive outreach for patients with schizophrenic disorder: Results of a quasi-experimental controlled trial', EUR PSYCHIAT, Jg. 30, Nr. 6, S. 736-42. https://doi.org/10.1016/j.eurpsy.2015.04.003

APA

Kästner, D., Büchtemann, D., Warnke, I., Radisch, J., Baumgardt, J., Giersberg, S., Kopke, K., Moock, J., Kawohl, W., & Rössler, W. (2015). Clinical and functional outcome of assertive outreach for patients with schizophrenic disorder: Results of a quasi-experimental controlled trial. EUR PSYCHIAT, 30(6), 736-42. https://doi.org/10.1016/j.eurpsy.2015.04.003

Vancouver

Kästner D, Büchtemann D, Warnke I, Radisch J, Baumgardt J, Giersberg S et al. Clinical and functional outcome of assertive outreach for patients with schizophrenic disorder: Results of a quasi-experimental controlled trial. EUR PSYCHIAT. 2015 Sep;30(6):736-42. https://doi.org/10.1016/j.eurpsy.2015.04.003

Bibtex

@article{8e9e2657220d4c609c8848e29f0bdfa6,
title = "Clinical and functional outcome of assertive outreach for patients with schizophrenic disorder: Results of a quasi-experimental controlled trial",
abstract = "BACKGROUND: The majority of studies support modern assertive health service models. However, the evidence is limited for parts of continental Europe, as well as for the pharmacological adherence outcome parameter.METHOD: We conducted a quasi-experimental controlled trial including adult patients with a schizophreniform disorder and a maximum of 60 points on the Global Assessment of Functioning Scale (GAF). Interventions (n=176) and controls (TAU, n=142) were assessed every six-month within one year in 17 study practices in rural areas. Mental and functional state were rated using the Brief Psychiatric Rating Scale (BPRS) and the GAF. Functional limitations and pharmacological adherence were patient-rated using the WHO-Disability Assessment Schedule II (WHODAS-II) and the Medication Adherence Report Scale (MARS). We computed multilevel mixed models.RESULTS: The GAF and BPRS of both groups improved significantly, yet the increase in the intervention group was significantly higher. In contrast, patient-rated variables - WHODAS-II and MARS - neither showed a stable temporal improvement nor a difference between groups.CONCLUSION: Our findings only partly support the investigated AO intervention, because of conflicting results between clinician- and patient-ratings. Accordingly, the benefits of AO need to be further evaluated.",
author = "D K{\"a}stner and D B{\"u}chtemann and I Warnke and J Radisch and J Baumgardt and S Giersberg and K Kopke and J Moock and W Kawohl and W R{\"o}ssler",
note = "Copyright {\textcopyright} 2015 Elsevier Masson SAS. All rights reserved.",
year = "2015",
month = sep,
doi = "10.1016/j.eurpsy.2015.04.003",
language = "English",
volume = "30",
pages = "736--42",
journal = "EUR PSYCHIAT",
issn = "0924-9338",
publisher = "Elsevier Masson",
number = "6",

}

RIS

TY - JOUR

T1 - Clinical and functional outcome of assertive outreach for patients with schizophrenic disorder: Results of a quasi-experimental controlled trial

AU - Kästner, D

AU - Büchtemann, D

AU - Warnke, I

AU - Radisch, J

AU - Baumgardt, J

AU - Giersberg, S

AU - Kopke, K

AU - Moock, J

AU - Kawohl, W

AU - Rössler, W

N1 - Copyright © 2015 Elsevier Masson SAS. All rights reserved.

PY - 2015/9

Y1 - 2015/9

N2 - BACKGROUND: The majority of studies support modern assertive health service models. However, the evidence is limited for parts of continental Europe, as well as for the pharmacological adherence outcome parameter.METHOD: We conducted a quasi-experimental controlled trial including adult patients with a schizophreniform disorder and a maximum of 60 points on the Global Assessment of Functioning Scale (GAF). Interventions (n=176) and controls (TAU, n=142) were assessed every six-month within one year in 17 study practices in rural areas. Mental and functional state were rated using the Brief Psychiatric Rating Scale (BPRS) and the GAF. Functional limitations and pharmacological adherence were patient-rated using the WHO-Disability Assessment Schedule II (WHODAS-II) and the Medication Adherence Report Scale (MARS). We computed multilevel mixed models.RESULTS: The GAF and BPRS of both groups improved significantly, yet the increase in the intervention group was significantly higher. In contrast, patient-rated variables - WHODAS-II and MARS - neither showed a stable temporal improvement nor a difference between groups.CONCLUSION: Our findings only partly support the investigated AO intervention, because of conflicting results between clinician- and patient-ratings. Accordingly, the benefits of AO need to be further evaluated.

AB - BACKGROUND: The majority of studies support modern assertive health service models. However, the evidence is limited for parts of continental Europe, as well as for the pharmacological adherence outcome parameter.METHOD: We conducted a quasi-experimental controlled trial including adult patients with a schizophreniform disorder and a maximum of 60 points on the Global Assessment of Functioning Scale (GAF). Interventions (n=176) and controls (TAU, n=142) were assessed every six-month within one year in 17 study practices in rural areas. Mental and functional state were rated using the Brief Psychiatric Rating Scale (BPRS) and the GAF. Functional limitations and pharmacological adherence were patient-rated using the WHO-Disability Assessment Schedule II (WHODAS-II) and the Medication Adherence Report Scale (MARS). We computed multilevel mixed models.RESULTS: The GAF and BPRS of both groups improved significantly, yet the increase in the intervention group was significantly higher. In contrast, patient-rated variables - WHODAS-II and MARS - neither showed a stable temporal improvement nor a difference between groups.CONCLUSION: Our findings only partly support the investigated AO intervention, because of conflicting results between clinician- and patient-ratings. Accordingly, the benefits of AO need to be further evaluated.

U2 - 10.1016/j.eurpsy.2015.04.003

DO - 10.1016/j.eurpsy.2015.04.003

M3 - SCORING: Journal article

C2 - 26003931

VL - 30

SP - 736

EP - 742

JO - EUR PSYCHIAT

JF - EUR PSYCHIAT

SN - 0924-9338

IS - 6

ER -